Trial Profile
Remicade Infusion Management Program.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RemiTRAC
- Sponsors Janssen Inc; Merck Sharp & Dohme; Schering-Plough
- 14 Jan 2013 Actual initiation date changed from Jul 2005 to Aug 2005 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.